Home Newsfeeds Wolfe Research Downgrades Cowen to Peer Perform

Wolfe Research Downgrades Cowen to Peer Perform

Wolfe Research analyst Steven Chubak downgrades Cowen (NASDAQ:COWN) from Outperform to Peer Perform.

byBenzinga Newsdesk

August 2, 2022

1 minute read

Wolfe Research analyst Steven Chubak downgrades Cowen (NASDAQ:COWN) from Outperform to Peer Perform.

Wells Fargo Maintains Equal-Weight on CVS Health, Lowers Price Target to $101

By Benzinga Newsdesk

January 3, 10:22 AM

Wells Fargo analyst Stephen Baxter maintains CVS Health (NYSE:CVS) with a Equal-Weight and lowers the price target from $106 to $101.

CVS

Shockwave Confirms Consistent Outcomes For IVL In The Largest Prospective “Real World” Study Of Patients With Heavily Calcified Peripheral Arterial Disease

By Benzinga Newsdesk

November 1, 2:58 PM

Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the final 1,373-patient cohort

SWAV

TaskUs Faces Future Uncertainties Amidst Strong Q2 Performance: Analyst Cautions On FY23 Forecast

By Lekha Gupta

August 10, 1:02 PM

RBC Capital Markets analyst Daniel R.

TASK

Boston Beer Co Q2 EPS $4.31 May Not Compare To $5.35 Estimate, Sales $616.20M Miss $629.32M Estimate

By Michael Horton

July 21, 4:16 PM

Boston Beer Co (NYSE:SAM) reported quarterly earnings of $4.31 per share which missed the analyst consensus estimate of $5.35 by 19.44 percent. This is a 9.26 percent decrease over earnings of $4.75 per share from the

SAM

Wolfe Research Downgrades Cowen to Peer Perform

Related Posts

Wells Fargo Maintains Equal-Weight on CVS Health, Lowers Price Target to $101

Shockwave Confirms Consistent Outcomes For IVL In The Largest Prospective “Real World” Study Of Patients With Heavily Calcified Peripheral Arterial Disease

TaskUs Faces Future Uncertainties Amidst Strong Q2 Performance: Analyst Cautions On FY23 Forecast

Boston Beer Co Q2 EPS $4.31 May Not Compare To $5.35 Estimate, Sales $616.20M Miss $629.32M Estimate